Lundbeck, a global pharmaceutical company based in Denmark and founded in 1915, strives for global leadership in psychiatry and neurology by improving the lives of patients. One of the few global companies specializing in brain disorders, Lundbeck is focused on innovating therapies for Alzheimer’s disease, depression, schizophrenia and Parkinson’s disease. The company is 70% owned by the Lundbeck Foundation that contributes nearly $100 million each year to research. In the U.S., Lundbeck employs more than 900 people dedicated to accelerating therapies for brain diseases. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in in the patient communities we support.